Abstract. Angiopoietin-like protein 4 (ANGPTL4) is a multifunctional protein, playing roles in glucose and lipid metabolism, inflammation, angiogenesis, and tumorigenesis. Recent research suggests that ANGPTL4 is induced by hypoxia and is a useful diagnostic or prognostic marker for various cancers. However, it remains unclear whether ANGPTL4 expression influences prostate cancer. Here we examined the biological and clinical relevance of ANGPTL4 expression in prostate cancer. Firstly we examined ANGPTL4 expression in the prostate cancer cell lines LNCaP and LNCaP/ CH incubated at 1% O 2 for at least 6 months. We compared cellular proliferation, migration, and ANGPTL4 secretion in a culture medium between these cell lines. In addition, we investigated the effect of various concentrations of recombinant ANGPTL4 protein (rANGPTL4) on cellular proliferation and intracellular signaling pathways. Moreover, we used ANGPTL4 knockdown by RNA interference to investigate the influence of ANGPTL4 expression on these cell lines. Finally, we investigated the correlation between ANGPTL4 expression in prostate cancer specimens and clinicopathological parameters using immunohistochemistry. Our data suggested that the expression of ANGPTL4 in hypoxic conditions was 14.4-fold higher than that in normoxic condition. ANGPTL4 secretion in the culture medium increased 7.0-fold. In addition, rANGPTL4 increased cellular proliferation 1.72-fold via Akt activation. Moreover, ANGPTL4 knockdown decreased cell growth and its secretion by 25.7 and 41.4%, respectively, compared with the control. A multivariate analysis showed that positive ANGPTL4 expression in the resected specimens was an independent prognostic indicator of biochemical recurrence (P=0.03, hazard ratio = 2.02). Our results show that ANGPTL4 is induced by hypoxia and promotes cancer progression via the activated PI3K/Akt pathway. Moreover, ANGPTL4 can be used as a prognostic marker for prostate cancer patients undergoing radical prostatectomy.
Introduction
Prostate cancer was the second most frequently diagnosed cancer in 2012 (1) and the sixth leading cause of death due to cancer in males worldwide (2) . Research into the pathways of prostate cancer growth suggests a novel therapeutic strategy to enhance the survival of this group (3) .
Since vessels do not form in tumors, adequate gas exchange does not occur between the tumor cells and surrounding environment. This leads to intratumoral hypoxia, known to promote cancer cell proliferation, invasion, metastasis, and resistance to radiation and chemotherapy (4, 5) . We previously reported that chronic hypoxia induces androgen-independent growth in the human prostate cancer cell line LNCaP (6) . Hypoxic conditions upregulate the expression of some proteins including angiopoietin-like protein 4 (ANGPTL4).
ANGPTL4 is a member of the angiopoietin family and is highly expressed in adipose and gastrointestinal tissues (7, 8) . Furthermore, ANGPTL4 is also known to influence inflammation, angiogenesis, and tumorigenesis (9) (10) (11) (12) . Several studies have reported a role of ANGPTL4 in cancer development, and its suppression can impair tumor growth by enhancing apoptosis (13) . Considering the fact that hypoxia is a feature of the tumor microenvironment (5) , it has been suggested that ANGPTL4 has effects on prostate cancer growth and/or malignant behavior. However, knowledge on the function of ANGPTL4 in human prostate cancer remains limited (14) .
Thus in the present study, we examined ANGPTL4 expression in prostate cancer cell lines under hypoxia and investigated the link between ANGPTL4 expression and associated clinicopathological factors.
Materials and methods

Cell cultures.
We purchased a human-androgen-dependent prostate cancer cell line (LNCaP) from the American Type Culture Collection (Rockville, MD, USA). These cells were cultured in RPMI-1640 medium (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 15% fetal bovine serum (FBS, Sigma-Aldrich), 50 IU/ml penicillin, and 50 mg/ml streptomycin sulfate (Gibco, Grand Island, NY, USA) at 37˚C with 5% CO 2 and 95% room air (normoxia), or 5% CO 2 , 94% N 2 , and 1% O 2 (hypoxia). LNCaP/CH cells were cultured under hypoxia for at least 6 months.
Proliferation assay. The cells were seeded into 12-well plates at a density of 1x10 5 cells per well. They were then trypsinized, collected, and counted using a hemocytometer 24, 48, and 72 h after seeding.
Water-soluble tetrazolium salt (WST-1) assay. The cells were seeded into 96-well plates at density of 5,000 cells per well. After culturing overnight, a fresh standard medium containing various concentrations of ANGPTL4 recombinant proteins (rANGPTL4) (0-1000 pg/ml) was added to each well. After incubation for 48 h, 5 mM WST-1 (Dojindo, Kumamoto, Japan) and 3 nM 1-methoxy-5-methylphenazinium methyl sulfate (Dojindo) were added to each well. After incubation for 1-4 h, absorbance was measured at 450 nm with a microplate reader (Tecan Japan Co., Ltd., Kanagawa, Japan).
Cell migration assay. Cell migration was assessed using a 24-well plate with Corning ® FluoroBlok Inserts (Corning Inc., Corning, NY, USA). The cells were seeded at 5x10 4 cells per well in 0.5-ml serum-free medium. The outer chambers were filled with 0.75 ml of media containing 15% FBS. After 24 or 48 h, migrating cells were labeled using Cellstain ® -Calcein-AM solution (Dojindo). After incubation for 1 h under normoxia or hypoxia, the cell fluorescence was detected using a microplate reader.
RNA isolation and quantitative real-time PCR.
This method was performed as previously described (6) . The primers comprised ANGPTL4 (Hs_ANGPTL4_1_SG QuantiTect Primer Assay, QT00003631) and β-actin (HS_ACTB_1_SG QuantiTect Primer Assay, QT00095431). The quantification of mRNA expression was normalized using β-actin.
Quantification of ANGPTL4 protein by ELISA. The cells were cultured in six-well plates at a density of 5x10 5 cells per well for 24, 48, and 72 h. The medium was then collected before adding fresh medium to the cultures. The collected medium was used to quantify ANGPTL4 protein concentration using a commercial ELISA according to the manufacturer's instructions (Human ANGPTL4 ELISA; Raybiotech, Inc., Norcross, GA, USA).
Establishment of ANGPTL4-overexpressing cells.
To create stably transfected lines, LNCaP cells were transduced with either FLAG-tagged ANGPTL4-expressing (Addgene) or control vectors (Cell Biolabs, Inc., San Diego, CA, USA) using Lipofectamine 3000 (Invitrogen), according to the manufacturer's protocol. The transfected cell lines were selected in 0.2-µg/ml puromycin dihydrochloride (Santa Cruz Biotechnology, Dallas, TX, USA).
Protein extraction and immunoblot analysis. This method was performed as previously described (6 
Flow cytometry analysis (FACS).
This method was performed as previously described (6) . The cell cycles were analyzed using a BD FACSVerse™ flow cytometer and BD FACSuite™ software (Becton Dickinson, San Jose, CA, USA).
Docetaxel or LY294002 treatment. The cells were seeded into 12-well plates at a density of 1x10 5 cells per well. After culturing overnight, a fresh standard medium containing 2 nM docetaxel (Sigma-Aldrich) was added to the plates. The phosphoinositide 3-kinase (PI3K) inhibitor, LY294002, was obtained from Calbiochem (Darmstadt, Germany). Docetaxel is the standard chemotherapy for men with advanced prostate cancer.
Patients. As this study was a retrospective chart review, no patient consent was required. From June 2009 to December 2012, 92 patients underwent curative surgery involving a radical prostatectomy for localized prostate cancer at Oita University Hospital (Oita, Japan). Patients who received therapy before and/ or immediately after surgery were excluded, and data from the remaining 70 patients were analyzed (Table I) . After surgery, the serum prostate specific antigen (PSA) levels were monitored, and PSA recurrence was defined as an elevation in serum PSA levels (≥0.2 ng/ml) in two consecutive measurements.
Immunohistochemistry. This method was performed as previously described (15) . The primary polyclonal goat anti-human ANGPTL4 (cat. no. 18374-1-AP, Proteintech™) antibody diluted to 100X with PBS containing 1% bovine serum albumin was applied.
Evaluation of immunostaining.
To evaluate ANGPTL4 staining, we counted the proportion of positively stained cells out of 1,000 cells from five randomly selected areas. ANGPTL4 expression was divided according to the percentage of positive tumor cells (negative, <20%; weak: 20-50%; and strong, >50%). Two authors independently evaluated in a blinded manner to the clinical findings, the level of immunoreactivity using an ECLIPSE E600 research microscope (Nikon Corp., Tokyo, Japan).
Statistical analysis. Statistical analyses were performed using a Student's t-test, Fisher's exact test, Mann-Whitney U-test, or Spearman's rank correlation test. A two-tailed test was used for all analyses. Biochemical recurrence-free survival was estimated using the Kaplan-Meier method and compared the groups using the log-rank test. A multivariate analysis was performed using a Cox's proportional hazards model. The P-values of <0.05 were considered to be statistically significant. All statistical analyses were performed using EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria) (16) .
Results
ANGPTL4 expression levels during chronic hypoxia.
LNCaP/CH cells were grown under hypoxic conditions for (Fig. 1A) . Similarly, ANGPTL4 protein expression was 6.6-fold higher in LNCaP/CH cells than in LNCaP cells (Fig. 1B) . Fig. 1B showed a doublet band and the molecular weight of the detected bands was 41 and 45 kDa. ANGPTL4 could be cleaved to an active form and the lower band indicates the active form of ANGPTL4.
ANGPTL4 secretion levels during chronic hypoxia. After 72 h, ANGPTL4 secretion was 7.0-fold higher in LNCaP/CH cells than in LNCaP cells (Fig. 1C) ; however, no statistically significant differences were found after 48 h (data not shown).
Effect of ANGPTL4 siRNA on LNCaP and LNCaP/CH cell behavior. ANGPTL4 siRNA (siANGPTL4) effectively downregulated ANGPTL4 expression in both LNCaP and LNCaP/ CH cells ( Fig. 2A) . After incubation for 72 h with siANGPTL4, cellular proliferation decreased to 82.0 and 74.2% in LNCaP and LNCaP/CH cells, respectively ( Fig. 2B and C) . Similarly, siANGPTL4 decreased ANGPTL4 secretion to 41.2% after 72 h in LNCaP/CH cells (Fig. 2D) . Flow cytometry revealed an increase in hypodiploid DNA (sub-G1 population) cells among the siANGPTL4 transfected cells, concomitant to a significant growth inhibition (Fig. 2E) .
ANGPTL4 overexpression accelerates the cellular migration of LNCaP cells.
To investigate the precise behavior of ANGPTL4 in prostate cancer, we established a stable cell line overexpressing ANGPTL4 (LNCaP/ANGPTL4). LNCaP/ANGPTL4 increased ANGPTL4 expression by 5.1-fold compared to the control (Fig. 3A) . Furthermore, cellular migration was 2.0-fold and 3.0-fold higher in LNCaP/ANGPTL4 cells than in LNCaP and LNCaP/neo-transfected cells with a control vector, respectively (Fig. 3B) . In contrast, cellular proliferation did not differ significantly among the cell lines (data not shown).
ANGPTL4 activates the PI3K/Akt pathway, and LY294002 inhibits the cellular proliferation of LNCaP cells.
To assess the potential role of ANGPTL4, we added different concentrations of rANGPTL4 to LNCaP cells (Fig. 4A) . Treatment with 100 pg/ml of rANGPTL4 for 72 h increased cellular proliferation 1.72-fold (Fig. 4B) . The immunoblot assay also revealed that Akt phosphorylation at Ser 473, a site required for Akt activation, was upregulated both time-and dose-dependently ( Fig. 4C and D) . However, cellular proliferation was suppressed in the cells subsequently treated with LY294002 (a PI3K inhibitor) 6 h later (Fig. 4E) . Akt phosphorylation peaked at 5-15 min (Fig. 4C ), but the effect on cellular proliferation was observed 48-72 h later (Fig. 4B) . It is considered that with the activation of Akt, various signaling molecules are activated resulting in cell survival.
ANGPTL4 overexpression and drug resistance. Cellular proliferation was successfully repressed in LNCaP/neo cells following 2 nM docetaxel treatment; however, LNCaP/ ANGPTL4 cells maintained their proliferative capabilities even after treatment (Fig. 3C) . The immunoblot assay revealed that anti-apoptotic B-cell lymphoma 2 (Bcl-2) expression was upregulated and that of Bcl-2-associated death promoter (Bad) was downregulated in LNCaP/ANGPTL4 cells compared with that in the controls (Fig. 3D) . Thus, these results indicate that ANGPTL4 expression is linked to docetaxel resistance by inhibiting apoptosis. Table I presents the clinicopathological characteristics of the patients included in this study. The median age of the patients was 67.5 (range: 49-76) years. The median PSA at diagnosis was 9.0 (range: 3.7-23.9) ng/ml. The pathological T (pT) stage was ≤pT2 in 61 cases (87.1%) and ≥pT3 in nine cases (12.9%). The Gleason score (GS) was ≤6 in 20 cases (28.6%) and ≥7 in 47 cases (67.1%). The remaining three cases were unremarkable. During a median follow-up of 53.5 (range: 13-82) months, 19 patients (27.1%) had PSA recurrence.
Patient characteristics.
Immunohistochemistry for ANGPTL4. We evaluated ANGPTL4 expression by immunohistochemistry in 70 prostate tissue samples. Normal prostate gland tissue did not express ANGPTL4. In contrast, we observed negative staining in 12 of the 70 prostate cancer samples (17.1%) and positive staining in 58 samples (82.9%). ANGPTL4 expression was particularly strong in 11 samples. Fig. 5A shows the representative images.
Association between ANGPTL4 expression and clinicopathological parameters. Table II lists the correlation between ANGPTL4 expression levels and different clinicopathological factors that were analyzed. ANGPTL4 expression levels were significantly correlated with PSA recurrence (P= 0.02). However, PSA at diagnosis, GS, pT stage, and the resection margin were not correlated with ANGPTL4 expression. An extraprostatic extension tended to be higher in cells with positive ANGPTL4 expression than in cells with negative ANGPTL4 expression; however, this difference was not significant (P=0.091).
ANGPTL4 expression levels and patient outcomes. We performed univariate and multivariate analyses to determine the factors that could be used as indicators of PSA recurrence after surgery (Table III) . A univariate analysis revealed that both pT stage (P=0.007) and positive ANGPTL4 expression of the tumor (P=0.04) were indicators of PSA recurrence. The multivariate analysis using the Cox's proportional hazards model revealed that positive ANGPTL4 expression was an independent prognostic indicator of PSA recurrence (P=0.03, hazard ratio = 2.02). The 3-year PSA recurrencefree survival rate for patients with positive ANGPTL4 expression was significantly lower than that for other patients (P=0.01) (Fig. 5B) .
Discussion
Herein, we examined ANGPTL4 expression in prostate cancer cell lines under hypoxic conditions. In addition, we assessed the behavior of ANGPTL4 in prostate cancer cell lines. We also assessed whether ANGPTL4 rendered prostate cancer cells resistant to chemotherapy. Finally, we investigated how ANGPTL4 expression correlated with clinicopathological factors.
Our results showed that chronic hypoxia induces ANGPTL4 expression and promotes cancer progression via the activated PI3K/Akt pathway. Previously, we reported that LNCaP cells conditioned under chronic hypoxia grew in an androgen-independent manner, presented accelerated G1 to S phases of the cell cycle, and accelerated cell migration and invasion. In addition, PI3K/Akt, JAK/STAT, and hypoxiainducible factor 1 (HIF-1) pathways were activated in LNCaP cells conditioned under chronic hypoxia (6) . In similar studies, Kim et al reported a synergistic effect of prostaglandin E 2 (PGE 2 ) and hypoxia on enhancing ANGPTL4 expression, and that increased ANGPTL4 expression promoted colorectal cancer growth. Moreover, these authors showed that hypoxia induced a PGE 2 receptor, the E prostanoid receptor (EP) 1. Activation of EP1 enhanced ANGPTL4 expression, whereas blockage of EP1 by an antagonist inhibited PGE 2 induction of ANGPTL4 under hypoxic conditions (17) . Thus, our Biochemical recurrence-free survival rate estimated using the Kaplan-Meier method and compared using the log-rank test. Probability values of P<0.05 were considered to be statistically significant. ANGPTL4, angiopoietin-like protein 4; PSA, prostate-specific antigen. Table II . Correlation between ANGPTL4 expression and clinicopathological factors. combined results suggest that ANGPTL4 plays an important role in cancer progression under hypoxia. In addition, our results showed that ANGPTL4 overexpression plays a role in drug resistance via the anti-apoptotic effect. A correlation between hypoxia and chemoresistance has been previously reported in a number of tumor cell types (18) . To this end, many reports have suggested that HIF-1-induced genes mediated chemoresistance either directly or indirectly (19) . Furthermore, some studies have reported that hypoxia induced the expression of ANGPTL4, and that the upregulation of ANGPTL4 is induced by the transcription factor HIF-1 (20, 21) . Our results complement previous research, and they show that ANGPTL4 directly mediates chemoresistance by inhibiting apoptosis in prostate cancer.
ANGPTL4 -----------------------------------
Negative ANGPTL4 expression was significantly related to longer PSA recurrence-free survival rates. To the best of our knowledge, these results are the first that suggest ANGPTL4 as a novel marker for PSA recurrence after radical prostatectomy. Generally, curative surgery or radiation therapy is used to treat localized prostate cancer. However, 25-35% of the patients develop evidence of biochemical recurrence after radical prostatectomy for clinically localized prostate cancer (22, 23) . Given the increased incidence of prostate cancer and the continued need for improved diagnostic markers to detect prostate cancer recurrence, research has focused on looking for specific blood and tumor markers. Our data indicate that ANGPTL4 can be used as a new prognostic marker. In the same analysis, other standard factors such as pT stage, PSA at diagnosis, and GS were not significantly associated with PSA recurrence. However, this lack of association might be related to the small sample size, and the fact that the patients who immediately received neo-adjuvant or adjuvant therapy after surgery, based on pathological findings, were excluded from the study potentially limited the scope of our results.
The role of ANGPTL4 in cancer remains controversial. For example, Ng et al reported that ANGPTL4 could represent a potential therapeutic agent to suppress hepatocellular carcinoma growth, angiogenesis, and metastasis (24) . On the other hand, a series of studies have reported the role of ANGPTL4 in promoting cancer progression (12, 25, 26) . Previously, ANGPTL4 has been shown to promote tumor cells for lung metastasis in breast cancer patients, and to trigger the disruption of vascular endothelial cell-cell junctions (27) . The origin of the discrepancy among these results is also unclear. The inferred cause is that ANGPTL4 is degraded in the human body. ANGPTL4 contains an N-terminal coiled domain (nANGPTL4) and a C-terminal fibrinogen-like domain (cANGPTL4); however, little is known about the relative expression of different ANGPTL4 fragments in each tissue. To this end, a recent study shows that cANGPTL4, but not nANGPTL4, is highly expressed in major epithelial tumors such as adenocarcinoma. The study examined ANGPTL4 expression using immunofluorescence with a monoclonal antibody against cANGPTL4 (mAb11F6C4) (13) . Thus, post-translational modifications of ANGPTL4 such as N-glycosylation might be behind different roles played by this protein in various cancers (28, 29) . The number of uncertainties regarding the role and biological mechanism of ANGPTL4 in human prostate cancer highlights the need of further studies in this front.
In conclusion, we show that hypoxia-induced ANGPTL4 promotes prostate cancer progression via the activated PI3K/Akt pathway. In addition, ANGPTL4 expression in surgically resected prostate cancer specimens can represent a novel prognostic marker. Finally, ANGPTL4 could also be suggested as a potential novel therapeutic target in prostate cancer. 
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